BioVersys AG (SWX:BIOV)

Switzerland flag Switzerland · Delayed Price · Currency is CHF
23.90
+0.40 (1.70%)
At close: Dec 4, 2025
-33.61%
Market Cap 135.67M
Revenue (ttm) 1.31M
Net Income (ttm) -19.36M
Shares Out 5.85M
EPS (ttm) -4.34
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 3,453
Average Volume 3,188
Open 22.50
Previous Close 23.50
Day's Range 22.50 - 24.00
52-Week Range 21.20 - 37.00
Beta n/a
RSI 51.09
Earnings Date Dec 11, 2025

About BioVersys AG

BioVersys AG, a clinical stage biopharmaceutical company, focuses on identification, development, and commercialization of novel antibacterial products for serious life-threatening infections caused by multi-drug-resistant bacteria. It develops BV100 that is in Phase 3 clinical trial for carbapenem resistant Acinetobacter baumannii lung and blood stream infections; and in Phase 1 trial in patients with hepatic impairment and a bronchoalveolar lavage (BAL). The company is also developing Alpibectir that is in Phase 2a clinical trial for the trea... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2008
Employees 27
Stock Exchange SIX Swiss Exchange
Ticker Symbol BIOV
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.